Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So "may sell" is the same as "sold"! LMAO
You just proved they haven't sold. LOL
The following table is based on information provided to us by the selling stockholders and is as of April 30, 2020, except as otherwise noted below. The selling stockholders may sell all or some of the shares of common stock they are offering, and may sell, unless indicated otherwise in the footnotes below
LMAO!
WALL STREET JOURNAL!!!
https://www.wsj.com/articles/PR-CO-20200506-901152
That's not the link to Sarah - that's someone else.
Nailed it! LOL
YES! And here's the proof! Enjoy!
Manuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients
https://www.marketwatch.com/press-release/manuscript-describes-how-cytodyns-leronlimab-disrupts-ccl5rantes-ccr5-pathway-thereby-restoring-immune-homeostasis-reducing-plasma-viral-load-reversing-hyper-immune-activation-and-inflammation-in-critical-covid-19-patients-2020-05-06-11842413
LOL - sure it is...
LOOKS LIKE SHORTS PICKED THE WRONG CORONA STOCK TO SHORT!!! LOL
LOOKS LIKE SHORTS ARE ABOUT TO LOSE SOME MAJOR MONEY!!!
And how was the share price "manipulated" above $3??
"Looks like the CYDY share price was manipulated above $3"
Why would you say that knowing the CEO sold late last week at its lowest price below $2.77, and two days later, it was hitting $3.37?
In case you missed it, the CEO sold late last week at its lowest price below $2.77. Two days later, it was hitting $3.37.
"I expect they know they got a really good price when they sold for all that profit."
It's right there. All you had to do was look.
"At study day zero, all ten critically ill patients received a subcutaneous 700mg injection of leronlimab following baseline blood collection. Because defining features of severe COVID-19 disease include plasma IL-6 and T cell lymphopenia2,19, and we observed >100-fold increased CCL5 levels compared to normal controls (Fig. 1d), we longitudinally monitored these parameters for two weeks after leronlimab treatment. A reduction of plasma IL-6 was observed as early as three days following leronlimab and returned to healthy control levels by day 14 (Fig. 2a). In contrast, more variable levels were observed with IL-1ß, IL-8, and CCL5 after leronlimab treatment (Supplementary Fig. 2). Following leronlimab administration, a marked restoration of CD8+ T cells (Fig. 2b) and a normalization of the CD4+ and CD8+ T cell ratio in blood was observed (Fig. 2c). These immunological changes occurred concomitant with full leronlimab CCR5 receptor occupancy on the surface of CCR5+ T cells and macrophages (Fig. 2d, 2e). Low levels of SARS-CoV-2 have been detected, but not yet quantified in the plasma of COVID-19 patients19. We used high sensitivity, digital droplet PCR to quantify plasma SARS-CoV-2 viremia at baseline. SARS-CoV-2 was found in the plasma of all ten critically ill patients, underscoring the severity of COVID-19 (Fig. 2f). Following leronlimab administration SARS-CoV-2 plasma viremia decreased in all patients at day seven, suggesting more effective anti-viral immunity following leronlimab-mediated CCR5 blockade."
IF YOU'RE SHORTING ALL DAY TODAY, THEN YOU'RE LOSING MONEY ALL DAY TODAY!!!!
$3.35 - SHORTS CAN'T COVER FAST ENOUGH!!
Can we please have a moment of silence while they step away from their keyboards to throw up?
UP 21%!!! NEED MORE STEAMMMMM! LOL
SHORTS COVERING! $3.15 and rising fast!
Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials
SAN DIEGO, May 5, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients.
Aji Bio-Pharma provides high quality drug product aseptic fill finish services for CytoDyn. Leronlimab, a novel CCR5 antagonist with the potential for multiple therapeutic indications, has been and is currently being administered to COVID-19 patients at New York City area hospitals as part of an emergency investigational new drug (EIND), granted by the U.S. Federal Drug Administration (FDA) as part of Phase 1, Phase 2 and Phase 2b/3 clinical trials. CytoDyn is currently enrolling patients in two placebo-controlled randomized clinical trials for Phase 2 and Phase 2b/3.
And where would the company have gotten the shares to sell given they have no more authorized shares to sell, and clearly have no plans to request the shareholders authorize additional shares to sell?
"just have the company sell some stock to raise capital"
He would have made a much larger profit if he had held them for 12 months, so why do think he sold them immediately? Perhaps to create cash for the company?
"He made a huge profit on those shares"
I assume you meant to say "Smart money COVERED !!!!!!! back to $3.00"
"Smart money SOLD !!!!!!!!!! back to 2.5"
I suspect Ajinomoto got out ahead of CYDY's PR - perhaps tomorrow.
Yes, it's flammable because those who are shorting it are fanning the flames by deliberately posting misleading information to create concern and doubt. This won't last long, especially given that we're expecting more good news this week, and the shorts are desperate to keep the price low while they cover and get out. They know what's headed their way.
He sold his shares now knowing that he would be sacrificing the benefit that he would have gained by keeping his shares for 12 months before selling them. Therefore he now has to pay a ~37% tax rate vs the 20% rate on the entire sale. It looks to me like he sacrificed the lower tax rate because he/they need the cash now. I "assume" he's going to loan the company the majority of the cash that he got from the sale. Otherwise there would be no benefit to himself by selling more than what they need until additional funding is secured. They're out of authorized shares to sell, so this appears to be a bridge to get them to the additional funding. This is just my opinion and what I'm reading in the tea leaves.
I was merely pointing out the long-term capital gains tax doesn't apply to his purchase/selling. Not sure why you got your feathers ruffled.
You said "figure 20%". Was that an assumption or just incorrect, because NP didn't say anything about the tax rate that he would be paying. It will be much higher than 20%.
You're assuming long-term capital gains which he will not get because he just purchased the shares when he exercised his warrants.
"So figure 20% of the total"
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the Company is expecting enrollment completion for its 75 patient, Phase 2 double blinded, placebo controlled, randomized study by the end of this month.
CytoDyn has submitted a request to the FDA to grant expanded access, also known as “compassionate use,” to make leronlimab available for patients not eligible for participation in two ongoing clinical trials for coronavirus infections. Many severe and critically-ill patients, who have received off-label immunomodulatory treatments for COVID-19, are excluded from participation in the Company’s Phase 2b/3 clinical trial and could potentially benefit from access to leronlimab under a compassionate use program.
There are 49 COVID-19 patients who have enrolled for treatment with leronlimab through eIND. Four out of 11 critically ill patients with a multitude of pre-existing conditions survived after treatment, and of the next 38 patients, many were extubated, improved, or were discharged.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are very excited about the continuing positive responses from eIND patients following their treatment with leronlimab. We are equally excited about the prospects for patients should the FDA grant access to leronlimab under the compassionate use program. During this past Saturday, we had to overcome many obstacles for two patients who desperately wanted leronlimab. One patient was in the same hospital that enrolled the first 11 patients and the second was a VIP patient in Los Angeles. Under the compassionate use program, we could avoid and quickly overcome this type of stress and turmoil which was very difficult for the patients, their families, the physicians, and CytoDyn. The daughter of a patient who was on a machine used for severe heart and lung failure contacted us directly and expressed her immense gratitude believing leronlimab saved her mother’s life. These are amazing times for us at CytoDyn; with the opportunity to wake up every day with the potential of saving somebody’s life. For sure, I could never have imagined such an incredible honor.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are very excited about the continuing positive responses from eIND patients following their treatment with leronlimab. We are equally excited about the prospects for patients should the FDA grant access to leronlimab under the compassionate use program. During this past Saturday, we had to overcome many obstacles for two patients who desperately wanted leronlimab. One patient was in the same hospital that enrolled the first 11 patients and the second was a VIP patient in Los Angeles. Under the compassionate use program, we could avoid and quickly overcome this type of stress and turmoil which was very difficult for the patients, their families, the physicians, and CytoDyn. The daughter of a patient who was on a machine used for severe heart and lung failure contacted us directly and expressed her immense gratitude believing leronlimab saved her m
Saltz - very good points and right on the money!
"Here’s what we know. Nader did not sell shares because he wanted to reduce his exposure. Quite the opposite. He converted warrants to shares and that cost $. To cover the conversion cost he had to sell some of his shares to do so. Nader utilized a cashless exercise, also known as a same-day sale.
It's now very clear that NP did NOT liquidate any of his position. Quite the contrary, he converted warrants into shares that he now owns thus increasing his position. That on its own is a sign of confidence in the current and future valuation of Leronlimab.
On another front Remdesivir is going to be heavily scrutinized in the coming days because of Fauchi’s premature proclamation that it is now the SOC for Covid-19. The changing of the metrics of the clinical trial, no placebo arm, ineffective in meeting the initial primary endpoint of decreasing mortality, and no peer review is pulling back the sheets on a very toxic drug that appears to do nothing more than knock off a few days in the hospital if the patient survives.
The researchers changed the primary outcome that the study claimed to evaluate. Originally, the study was designed to rate participants’ health on day 15 and day 29 of treatment. Now, it’s focused on how many days it takes to recovery. There can be good reasons for changing this variable—NIAID provided an explanation on Friday, after the drug was authorized—but, without the full dataset, outside scientists can’t make sense of the change."
As usual, your DD is accurate and much appreciated!
There was no sale, so there's nothing to be considered.
It says it hasn't been sold.
NOT SOLD...NOT SOLD! You removed page 2 where it clearly states warrants were exercised. Please include page 2. LOL
"Per the call yesterday NP stated that if people exercised their options, then we could uplist without diluting."
Yes, and NP is clearly leading by example. Too much fake news being spread.
The 144 form CLEARLY states these are warrants that were exercised. Show where it says "Shares Sold". LOL
Take a look at the 144 form and you will see that he clearly hasn't sold ANY shares.
How many hours has it been? LOL And, btw, as you've been told, he's already responded directly to other posters saying this is a complete lie. So, this is "dragging his feet"? LMAO
"why is NP apparently dragging his feet to officially debunk it via 8K filing?"
Look at page 2 - this clearly is an exercise of warrants - NOT selling shares. Thanks for the proof that he didn't sell shares!
So you're suggesting NP file a denial in another SEC 8k filing? LOL 8k forms aren't used for that purpose. With all of the garbage and fake news that's being posted about him, why should he have to spend his limited time denying anything? The SEC will take care of that given that many investors are now filing complaints to the SEC (with screen shots and examples) as we speak.
"What's stopping NP from denying the Form 144 in a SEC 8k filing?"
NP has already responded to others posters directly and said this is an absolute lie, and the 49 million existing shares were registered on a S3, and had nothing to do with selling shares.
Feel free to include this in your future posts.